Upadacitinib for the Treatment of Alopecia Areata and Severe Atopic Dermatitis in a Pediatric Patient: A Case Report

    January 2022 in “ SAGE open medical case reports ”
    Adrienn N. Bourkas, Cathryn Sibbald
    Studysummary This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.sagepub.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. The JAK/STAT Signaling Pathway: From Bench to Clinic Signal Transduction and Targeted Therapy · 2021
    2. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    3. Targeting the Janus Kinase Family in Autoimmune Skin Diseases Frontiers in Immunology · 2019
    4. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    5. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017

    Related research 2

    1. Topical Minoxidil for the Treatment of Alopecia Areata PubMed · 2017
    2. Effectivity of Minoxidil as a Treatment for Alopecia Areata DOAJ (DOAJ: Directory of Open Access Journals) · 2013